TMO - Parexel is said near sale to EQT AB and Goldman Sachs for nearly $9B

Zhanna Hapanovich/iStock via Getty Images EQT AB and Goldman Sachs Inc.'s (GS) investment arm are reportedly in advanced discussions to buy contract-research organization Parexel for close to $9B including debt. A sale to EQT and Goldman may be announced this week, according a WSJ report, which cited people familiar. The CRO had received interest from private equity and strategic buyers. Last week, Bloomberg reported that Parexel had garnered takeover interest from PE firms and AmeriSourceBergen (ABC). Bloomberg reported in April Parexel's PE owner Pamplona Capital Management was exploring a sale of the company in a deal that could value Parexel at about $9B including debt. The potential sale comes after some other big deals for CROs earlier this year such as Thermo Fisher's (TMO) planned $17B deal for PPD (PPD) and Icon PLC's (ICLR) purchase PRA Health (PRAH), which closed yesterday.

For further details see:

Parexel is said near sale to EQT AB and Goldman Sachs for nearly $9B